CITIUS ONCOLOGY, INC. (TENK) - 10-Q Summary
Business Context and Reporting Period
Company: Citius Oncology, Inc. (formerly TenX Keane Acquisition)
Reporting Period: Quarter ended June 30, 2024
Status: Special Purpose Acquisition Company (SPAC) in pre-business combination phase. The Company has not commenced operations and generates no operating revenue. It is an emerging growth company and a shell company.
Key Event: The Company entered into a Merger Agreement in October 2023 to acquire Citius Oncology, Inc. (a subsidiary of Citius Pharma). On August 5, 2024, the Company domesticated from the Cayman Islands to Delaware.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Operating Expenses | $383,957 | $652,386 | - |
| Interest Income (Trust) | $636,419 | $1,394,677 | - |
| Net Income | $252,462 | $742,291 | - |
| Cash (Outside Trust) | - | - | $261 |
| Investments in Trust Account | - | - | $49,152,639 |
| Total Assets | - | - | $49,193,627 |
| Current Liabilities | - | - | $3,080,938 |
| Notes Payable (Related Party) | - | - | $1,720,001 |
| Shares Subject to Redemption | - | - | 4,312,077 |
Material Changes vs. Prior Period
- Trust Account Reduction: Investments held in the trust account decreased from $72,565,394 (Dec 31, 2023) to $49,152,639 (June 30, 2024). This reduction is primarily due to the redemption of 2,287,923 ordinary shares in January 2024 and subsequent withdrawals to fund redemptions totaling $25,207,434 during the six-month period.
- Operating Expenses: General and administrative costs increased significantly to $383,957 for the three months ended June 30, 2024, compared to $199,554 in the same period in 2023, reflecting increased costs associated with the pending business combination.
- Related Party Debt: Notes payable increased to $1,720,001 from $1,320,000, and amounts due to related parties increased to $870,186 from $344,875, driven by extension fees and working capital loans.
- Liquidity: Cash held outside the trust account is critically low at $261, down from $32,746 at year-end 2023.
Outlook, Risks, and Management Commentary
- Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. It lacks adequate liquidity to sustain operations and must consummate a business combination by August 18, 2024, or liquidate.
- Extension Strategy: The Company has been extending its liquidation deadline monthly via deposits into the trust account by Citius Pharma (e.g., $66,667 per month). The current deadline is August 18, 2024.
- Business Combination Status: On August 2, 2024, shareholders approved the business combination. Approximately 4,297,828 public shares were redeemed at an estimated price of $11.47 per share. The transaction is expected to close shortly.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in accounting for accruals, related party advances, and complex financial instruments.
- Risks: Failure to complete the merger by the deadline will result in mandatory liquidation. The Company relies on related party loans for working capital, which may not be sufficient.
Investor Verification Checklist
- Merger Closing Date: Verify if the business combination with Citius Oncology has officially closed and if the Company has delisted from Nasdaq or changed its ticker symbol.
- Redemption Impact: Confirm the final number of shares remaining post-redemption and the resulting cash balance available for the combined entity.
- Related Party Loans: Review the terms of the $1.72M in notes payable and $870k due to related parties to understand if these will be converted to equity or repaid upon closing.
- Internal Control Remediation: Assess the plan to remediate the material weaknesses in internal controls identified in the 10-Q.
- Extension Fees: Verify if any further extension fees were paid after June 30, 2024, and the total cost of extensions incurred.